Journey Medical Corporation - Common Stock (DERM)

Journey Medical (NASDAQ:DERM) reported higher second-quarter revenue and a sharply narrower net loss as sales of its rosacea treatment EMROSI continued to grow, supported by rising prescription volume, broader prescriber adoption and improving payer reimbursement. Total revenue for the second quart

Journey Medical (DERM) Q1 2026 Earnings Transcript

Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.

Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday that it will be acquired by global private equity firm Advent in an all-cash transaction

After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the treatment of rosacea.

DERM stock results show that Journey Medical missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.